This is particularly relevant as GBA gene mutation variants have been shown to be associated with a specific cognitive subtype in PD with a rapid cognitive decline progressing to dementia.9 Similarly, the identification of the carriers of the leucine‐rich repeat kinase 2 gene (LRRK2) could be targeted with LRRK2 inhibitors. The gene discussed is LRRK2; the disease is Parkinson disease.